MedPath

Orismilast

Generic Name
Orismilast
Clinical Trials
Related News

Orismilast for the Treatment of Mild to Severe Hidradenitis Suppurativa

Phase 2
Conditions
Hidradenitis Suppurativa
Interventions
First Posted Date
2021-07-29
Last Posted Date
2021-09-28
Lead Sponsor
Gregor Jemec
Target Recruit Count
24
Registration Number
NCT04982432

A Trial to Investigate the Safety, Tolerability, and Drug Levels in Blood After Single and Multiple Doses of LEO 32731 in Healthy People

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: LEO 32731 modified release tablet
Drug: LEO 32731 blend, hard capsule
Drug: LEO 32731 soft capsule
Other: Placebo
Drug: LEO 32731 API, hard capsule
Drug: LEO 32731 gastro-resistant capsule
First Posted Date
2019-01-23
Last Posted Date
2019-07-01
Lead Sponsor
LEO Pharma
Target Recruit Count
66
Registration Number
NCT03812198
Locations
🇬🇧

LEO Pharma Investigational Site, Leeds, United Kingdom

Multiple Dose Study With Incremental Dosing to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Doses of LEO 32731 in Healthy Male Japanese Subjects.

Phase 1
Completed
Conditions
Psoriasis Vulgaris
Interventions
Drug: Placebo
First Posted Date
2017-07-27
Last Posted Date
2021-06-29
Lead Sponsor
LEO Pharma
Target Recruit Count
26
Registration Number
NCT03231124
Locations
🇬🇧

Investigational Site, London, United Kingdom

Open-label, Single Center, Non-randomized, Fixed Sequence Phase 1 Drug-drug Interaction Study With LEO 32731 and Midazolam

Phase 1
Completed
Conditions
Drug Interaction Potentiation
Interventions
First Posted Date
2017-04-24
Last Posted Date
2017-11-14
Lead Sponsor
LEO Pharma
Target Recruit Count
32
Registration Number
NCT03126578
Locations
🇩🇪

Nuvisan GmbH, Neu-Ulm, Germany

LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris

Phase 2
Completed
Conditions
Psoriasis Vulgaris
Interventions
Drug: LEO 32731 Placebo
First Posted Date
2016-09-02
Last Posted Date
2017-08-28
Lead Sponsor
LEO Pharma
Target Recruit Count
36
Registration Number
NCT02888236
Locations
🇩🇪

Charité Universitätsmedizin Berlin, Dept. of Dermatology, Berlin, Germany

A Phase I Study With LEO 32731 and Midazolam in Healthy Male Subjects

Phase 1
Terminated
Conditions
Psoriasis Vulgaris
Interventions
First Posted Date
2016-04-27
Last Posted Date
2017-05-03
Lead Sponsor
LEO Pharma
Target Recruit Count
12
Registration Number
NCT02753218
Locations
🇬🇧

Covance Clinical Research Unit Ltd., Springfield House, Hyde Street, Leeds, United Kingdom

LEO 32731 - A Phase I Study in Healthy Subjects

Phase 1
Completed
Conditions
Psoriasis Vulgaris
Interventions
Other: Placebo
First Posted Date
2015-08-04
Last Posted Date
2017-05-03
Lead Sponsor
LEO Pharma
Target Recruit Count
27
Registration Number
NCT02514694
Locations
🇬🇧

Covance CRU, Leeds, United Kingdom

LP0058-1005 - A Open-Label, Four-Way Crossover and Food-Effect Study of LEO 32731 in Healthy Subjects

Phase 1
Completed
Conditions
Psoriasis Vulgaris
Interventions
First Posted Date
2014-04-30
Last Posted Date
2016-06-14
Lead Sponsor
LEO Pharma
Target Recruit Count
24
Registration Number
NCT02126371
Locations
🇬🇧

Covance CRU, Leeds, United Kingdom

LEO 32731 - A Study in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
First Posted Date
2011-03-07
Last Posted Date
2013-11-05
Lead Sponsor
LEO Pharma
Target Recruit Count
111
Registration Number
NCT01310049
Locations
🇬🇧

Covance Clinical Research Unit Ltd., Leeds, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy